| Literature DB >> 34480526 |
Hiroki Kitakata1, Takashi Kohno1,2, Shun Kohsaka1, Daisuke Fujisawa3, Naomi Nakano1, Yasuyuki Shiraishi1, Yoshinori Katsumata4, Yuji Nagatomo5, Shinsuke Yuasa1, Keiichi Fukuda1.
Abstract
AIMS: Early engagement in advance care planning (ACP) is recommended in heart failure (HF) management. We investigated the preferences of patients with HF regarding ACP and end-of-life (EOL) care, including their desired timing of ACP initiation. METHODS ANDEntities:
Keywords: Advanced care planning; End-of-life care; Heart failure; Patient preference
Mesh:
Year: 2021 PMID: 34480526 PMCID: PMC8712895 DOI: 10.1002/ehf2.13578
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
Questionnaire for hospitalized heart failure patients
| Questions |
|---|
|
|
|
|
|
|
| 1. Absolutely disagree 2. Disagree 3. Somewhat disagree 4. Unsure 5. Somewhat agree 6. Agree 7. Absolutely agree |
|
|
| 1. During the 1st admission for heart failure 2. During the 2nd admission for heart failure 3. After repeated admissions for heart failure in the past year 4. In situations where you feel your life is threatened 5. Other |
|
|
| 1. Performed 2. Not performed |
|
|
| 1. Absolutely disagree 2. Disagree 3. Somewhat disagree 4. Unsure 5. Somewhat agree 6. Agree 7. Absolutely agree |
|
|
| 1. Determined 2. Not determined |
|
|
| 1. Absolutely disagree 2. Disagree 3. Somewhat disagree 4. Unsure 5. Somewhat agree 6. Agree 7. Absolutely agree |
|
|
| 1. Completed 2. Not completed |
|
|
|
|
| 1. Absolutely disagree 2. Disagree 3. Somewhat disagree 4. Unsure 5. Somewhat agree 6. Agree 7. Absolutely agree |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1. Home 2. Hospital 3. Nursing facility 4. Other |
HF, heart failure.
Baseline characteristics
| Variables | |
|---|---|
| Demographics | |
| Age (years) | 73.0 (63.0–81.0) |
| Male, | 115 (67.3) |
| Japanese, | 171 (100) |
| Body mass index (kg/m2) | 20.6 (18.7–23.4) |
| University education or more, | 80 (46.8) |
| Married, | 113 (66.1) |
| Living alone, | 41 (24.0) |
| Medical history, | |
| Hypertension | 91 (53.2) |
| Diabetes mellitus | 64 (37.4) |
| Dyslipidaemia | 67 (39.2) |
| Atrial fibrillation | 112 (65.5) |
| Chronic obstructive pulmonary disease | 22 (12.9) |
| Stroke | 26 (15.2) |
| Cancer | 42 (24.6) |
| Aetiology of HF, | |
| Ischaemic | 39 (22.8) |
| Dilated | 31 (18.1) |
| Valvular | 40 (23.4) |
| Arrhythmia‐induced | 12 (7.0) |
| Other aetiology | 49 (28.7) |
| Previous HF admission, | 84 (49.1) |
| NYHA at discharge III and IV, | 54 (31.6) |
| Vital signs at discharge | |
| Heart rate (b.p.m.) | 73.2 ± 13.0 |
| Systolic blood pressure (mmHg) | 104.0 (94.0–116.0) |
| Echocardiographic parameters | |
| Left ventricular ejection fraction (%) | 44.1 (31.3–59.5) |
| Laboratory data at discharge | |
| Haemoglobin (g/dL) | 12.3 ± 2.3 |
| Sodium (mEq/L) | 139.4 (137.4–141.0) |
| Uric acid (mg/dL) | 7.0 (5.9–8.1) |
| BUN (mg/dL) | 24.3 (19.5–34.7) |
| Creatinine (mg/dL) | 1.20 (0.93–1.63) |
| BNP (pg/mL) | 405.1 (208.5–733.7) |
| Lymphocyte (%) | 22.0 (17.8–26.7) |
| Total cholesterol (mg/dL) | 166.1 (137.0–190.0) |
| Medication or device therapy, | |
| Loop diuretics | 147 (86.0) |
| Beta‐blockers | 143 (83.6) |
| RAS inhibitors | 102 (59.6) |
| Mineralocorticoid receptor antagonists | 89 (52.0) |
| Statin | 67 (39.2) |
| Allopurinol or febuxostat | 76 (44.4) |
| ICD | 15 (8.8) |
| CRT | 10 (5.8) |
| SHFM‐estimated 1 year survival rate (%) | 94.2 (90.9–96.3) |
BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CRT, cardiac resynchronization therapy; HF, heart failure; ICD, implantable cardioverter defibrillator; NYHA, New York Heart Association functional classification; RAS, renin–angiotensin system; SHFM, Seattle Heart Failure Model.
Data are shown as mean ± standard deviation, median with inter‐quartile range, or number (percentage).
Figure 1Patients' preferences and engagement in advance care planning (ACP) conversations. (A) The proportions of patients' preferences and actual performance of ACP conversations in patients hospitalized for heart failure. (B) The proportion of patient‐expected optimal timing for ACP initiation among patients with positive attitudes towards ACP conversation. (C) Relationship between Seattle Heart Failure Model (SHFM)‐predicted 1 year survival rate and attitudes towards ACP conversation. Bar denotes medians, boxes denote inter‐quartile ranges, and whiskers extend to 1.5 inter‐quartile range. Dots represent each patient's 1 year survival rate.
Determinants of those who considered ‘ACP conversation was important’ among patients' characteristics
| Variables | OR | 95% CI |
|
|---|---|---|---|
| Age (per each year increase) | 1.00 | 0.97–1.03 | 0.890 |
| Male | 0.94 | 0.45–1.97 | 0.879 |
| Hypertension | 1.19 | 0.60–2.36 | 0.620 |
| Dyslipidaemia | 1.17 | 0.58–2.39 | 0.657 |
| Diabetes mellitus | 1.60 | 0.77–3.35 | 0.212 |
| Atrial fibrillation | 1.12 | 0.55–2.28 | 0.763 |
| Chronic obstructive pulmonary disease | 3.93 | 0.88–17.53 | 0.073 |
| History of stroke | 0.93 | 0.36–2.39 | 0.880 |
| History of cancer | 0.71 | 0.33–1.52 | 0.374 |
| Previous heart failure admission | 0.95 | 0.48–1.89 | 0.893 |
| LVEF (per each % increase) | 1.01 | 0.99–1.03 | 0.388 |
| NYHA III and IV | 1.14 | 0.54–2.40 | 0.736 |
| BNP (per each pg/mL increase) | 1.00 | 1.00–1.00 | 0.882 |
| SHFM‐estimated 1 year survival rate (per each % increase) | 0.97 | 0.92–1.03 | 0.358 |
| Quality of life (per each EQ‐5D score increase) | 4.40 | 0.64–30.12 | 0.131 |
| Depression (per each PHQ‐2 score increase) | 0.75 | 0.61–0.92 | 0.006 |
| University education or more | 2.66 | 1.28–5.56 | 0.009 |
| Married | 2.53 | 1.25–5.12 | 0.010 |
| Having children | 1.97 | 0.91–4.27 | 0.086 |
| Living alone | 0.58 | 0.27–1.24 | 0.160 |
ACP, advance care planning; BNP, brain natriuretic peptide; CI, confidence interval; EQ‐5D, EuroQol Five Dimensions; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association functional classification; OR, odds ratio; PHQ‐2, Patient Health Questionnaire‐2; SHFM, Seattle Heart Failure Model.
Figure 2Important factors identified by patients for their end‐of‐life care in advanced heart failure.